Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE vs CALDEROL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcipotriene is a synthetic vitamin D3 analog that binds to vitamin D receptors, regulating cell proliferation and differentiation. Betamethasone dipropionate is a corticosteroid that reduces inflammation by inducing phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.
Vitamin D analog; binds to vitamin D receptors, increasing calcium absorption in intestines and promoting bone mineralization.
Treatment of plaque psoriasis (FDA-approved)
Osteoporosis,Vitamin D deficiency,Renal osteodystrophy,Hypoparathyroidism
Apply once daily to affected areas of skin, not exceeding 100 g/week or 30 m L/day. Do not use under occlusive dressings.
Oral: 0.25-0.5 mcg once daily; titration up to 1 mcg daily based on serum calcium levels. Intravenous: 0.5-2 mcg bolus; maintenance 0.5-2 mcg daily.
Calcipotriene: 12-24 hours; betamethasone dipropionate: 4-6 hours (parent), 3-5 hours (active metabolite betamethasone 17-propionate).
Terminal elimination half-life is approximately 20-30 hours; clinically, steady-state is achieved within 5-7 days.
Calcipotriene undergoes hepatic metabolism primarily via cytochrome P450 (CYP) enzymes, including CYP24A1. Betamethasone dipropionate is metabolized in the liver via CYP3A4.
Hydroxylated in liver to 25-hydroxyvitamin D; further hydroxylated in kidney to active 1,25-dihydroxyvitamin D.
Calcipotriene: renal elimination of metabolites; betamethasone dipropionate: primarily renal (70%) and biliary/fecal (30%) as metabolites.
Primarily fecal (biliary) as unchanged drug and metabolites (approx. 80%); renal excretion accounts for less than 20%.
Calcipotriene: ~94% bound to plasma proteins; betamethasone dipropionate: ~64% bound (predominantly albumin).
Approximately 99% bound to serum proteins, primarily to vitamin D-binding protein (DBP) and albumin.
Calcipotriene: >1 L/kg (extensive tissue distribution); betamethasone dipropionate: not well characterized, likely large due to lipophilicity.
Vd is approximately 0.4 L/kg; reflects distribution into total body water with negligible storage in fat.
Topical: minimal systemic absorption (<1% for calcipotriene, ~10-15% for betamethasone dipropionate via inflamed skin).
Oral bioavailability of calcitriol is approximately 70-90%.
No specific dose adjustment required for renal impairment. Use with caution in severe renal impairment due to potential for systemic absorption.
e GFR <30 m L/min/1.73m2: reduce dose by 50% and monitor calcium/phosphate levels; e GFR <15 m L/min/1.73m2: avoid use due to risk of hypercalcemia.
No specific dose adjustment required for hepatic impairment. Use with caution in severe hepatic impairment due to potential for systemic corticosteroid effects.
Child-Pugh class B or C: reduce initial dose by 50% and titrate slowly; monitor calcium and albumin levels.
Safety and efficacy in children <12 years have not been established. For children ≥12 years, apply once daily to affected areas, limit use to <30 g/week, and avoid prolonged use.
For hypocalcemia: 0.05-0.1 mcg/kg/day PO, titrated in 0.05 mcg/kg increments every 2-4 weeks; not recommended for IV use in neonates.
No specific dose adjustment required, but use with caution due to increased risk of skin atrophy and systemic effects. Avoid prolonged use and apply to limited areas.
Start at the lowest adult dose (0.25 mcg PO daily); increase cautiously due to reduced renal function; monitor serum calcium and renal function frequently.
None.
None
Systemic absorption can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria.,Local adverse reactions may include skin atrophy, striae, telangiectasias, burning, pruritus, folliculitis, and allergic contact dermatitis.,May cause hypercalcemia and hypercalciuria due to calcipotriene component; monitor serum and urine calcium levels in patients with renal impairment or high doses.,Avoid use on face, groin, axillae, or intertriginous areas due to increased risk of adverse effects.,Not recommended for long-term continuous use due to potential for skin atrophy and systemic effects.
Hypercalcemia,Hypercalciuria,Renal impairment,Monitoring of serum calcium and phosphorus required
Hypersensitivity to calcipotriene, betamethasone dipropionate, or any component of the formulation.,Patients with known calcium metabolism disorders (e.g., hypercalcemia, vitamin D toxicity).,Patients with known or suspected skin infections, including viral (e.g., herpes simplex, varicella), fungal, or bacterial infections.,Use on eroded, ulcerated, or exudative skin.
Hypercalcemia,Vitamin D toxicity,Malabsorption syndrome,Severe renal impairment
No significant food interactions. No dietary restrictions necessary for this topical medication.
Avoid high-calcium foods or supplements unless directed. Vitamin D analogs may alter calcium absorption. No specific food restriction.
Topical calcipotriene/betamethasone dipropionate has low systemic absorption; however, betamethasone is a corticosteroid. Animal studies with high-dose topical corticosteroids show increased risk of cleft palate and fetal growth restriction. In humans, first-trimester use of potent corticosteroids is associated with a small increased risk of oral clefts (OR 1.5). Second/third trimester: Prolonged use may cause fetal adrenal suppression and low birth weight. Avoid application to large areas (>30% BSA) or under occlusion.
FDA Pregnancy Category C. First trimester: Potential for cardiac malformations (case reports). Second/third trimester: Risk of premature closure of ductus arteriosus, oligohydramnios, and pulmonary hypertension. Avoid use after 20 weeks gestation.
Minimal systemic absorption after topical use. No specific M/P ratio available. Exercise caution: avoid application to breast area to prevent infant ingestion. Monitor infant for signs of adrenal suppression (rare). Use lowest effective dose for shortest duration.
Excreted in breast milk; M/P ratio unknown. Potential for adverse vascular effects in infants. Contraindicated in breastfeeding due to risk of ductus arteriosus constriction.
No dose adjustment needed for topical use. However, restrict application to <30% body surface area and avoid prolonged treatment; use shortest possible duration. Systemic absorption may increase with psoriatic skin barrier disruption; monitor for corticosteroid side effects.
No standard dose adjustment. Use lowest effective dose for shortest duration. Contraindicated after 20 weeks gestation; avoid in first trimester if possible due to teratogenic potential.
Apply only to psoriatic plaques, not to normal skin or flexures. Maximum weekly dose: 100g. Avoid occlusion. Use with caution on face, genitals, and intertriginous areas due to risk of corticosteroid atrophy. Discontinue if hypersensitivity develops. Monitor for hypercalcemia if used on extensive areas. Not recommended for use in children under 18 years.
Calderol (calcifediol) is a vitamin D analog used for renal osteodystrophy. Monitor serum calcium and phosphate levels; do not use with severe hypercalcemia or vitamin D toxicity. Dose adjustment needed in dialysis patients.
For external use only.,Apply once daily to psoriatic lesions only, avoiding unaffected skin.,Do not use more than 100 grams per week.,Do not cover with bandages or tight dressings.,Wash hands after application unless treating hands.,Avoid contact with eyes, mouth, and mucous membranes.,Do not use on face, armpits, or groin unless directed.,Inform your healthcare professional if you experience burning, itching, or skin thinning.,Use only on children under 18 if specifically prescribed.,Do not use for more than 4 weeks without medical evaluation.
Take exactly as prescribed; do not take extra doses.,Avoid calcium supplements and antacids without consulting your doctor.,Report symptoms of hypercalcemia: nausea, vomiting, constipation, weakness, confusion.,Not for use in children.,Store at room temperature away from light and moisture.
"Coadministration of Betamethasone, a potent corticosteroid, may reduce the therapeutic efficacy of Miglustat, a glucosylceramide synthase inhibitor used for Gaucher disease and Niemann-Pick type C. Betamethasone can induce hepatic CYP3A4 isoenzymes, potentially increasing the metabolism of Miglustat, though Miglustat is primarily renally excreted and not extensively metabolized. The interaction may also involve corticosteroid-mediated alterations in drug transport or GlcCer synthesis pathways, leading to decreased Miglustat plasma concentrations and diminished clinical response, including worsening of neurological symptoms in Niemann-Pick disease."
"Concomitant use of betamethasone, a corticosteroid, with donepezil, a cholinesterase inhibitor used in Alzheimer's disease, may increase the risk of gastrointestinal adverse effects including gastric ulceration and hemorrhage. Corticosteroids inhibit prostaglandin synthesis and mucosal protection, while donepezil enhances cholinergic tone, increasing gastric acid secretion. This additive effect on the gastric mucosa can lead to clinically significant ulcer formation or gastrointestinal bleeding, particularly in elderly patients."
"Betamethasone, a potent corticosteroid, can induce hyperglycemia and dyslipidemia, potentially counteracting the lipid-lowering effects of atorvastatin. Concurrent use may increase the risk of corticosteroid-related adverse effects such as fluid retention, hyperglycemia, and myopathy. Atorvastatin may also increase systemic exposure to corticosteroids via inhibition of CYP3A4, though this interaction is generally not clinically significant."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE vs CALDEROL, answered by our medical review team.
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE is a Vitamin D Analog that works by Calcipotriene is a synthetic vitamin D3 analog that binds to vitamin D receptors, regulating cell proliferation and differentiation. Betamethasone dipropionate is a corticosteroid that reduces inflammation by inducing phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.. CALDEROL is a Vitamin D Analog that works by Vitamin D analog; binds to vitamin D receptors, increasing calcium absorption in intestines and promoting bone mineralization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE and CALDEROL depend on the specific clinical indication. These are both Vitamin D Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE is: Apply once daily to affected areas of skin, not exceeding 100 g/week or 30 m L/day. Do not use under occlusive dressings.. The standard adult dose of CALDEROL is: Oral: 0.25-0.5 mcg once daily; titration up to 1 mcg daily based on serum calcium levels. Intravenous: 0.5-2 mcg bolus; maintenance 0.5-2 mcg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE and CALDEROL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE is classified as Category C. Topical calcipotriene/betamethasone dipropionate has low systemic absorption; however, betamethasone is a corticosteroid. Animal studies with high-dose topical corticosteroids show. CALDEROL is classified as Category C. FDA Pregnancy Category C. First trimester: Potential for cardiac malformations (case reports). Second/third trimester: Risk of premature closure of ductus arteriosus, oligohydramni. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.